Moleculin Biotech

Company snapshot

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in developmen

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Moleculin Biotech. Not investment advice.

• Peer + 0 momentum

  Aptose Biosciences

  TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for Moleculin Biotech.

1. Jun 8, 2026 Clinical update

   MB-108 — Phase 3

2. Jun 8, 2026 Clinical update

   MB-106 — Phase 2

3. Jun 8, 2026 Clinical update

   Placebo in combination with Cytarabine Injection — Phase 3

4. Jun 8, 2026 Clinical update

   Liposomal Annamycin — Phase 2

5. Jun 8, 2026 Clinical update

   Liposomal Annamycin (L-Annamycin) — Phase 2

View all clinical trial activity →

• What is Moleculin Biotech?

  Moleculin Biotech is a biotech organization headquartered in Houston, USA. It trades on NYSE under ticker MBRX. Primary therapeutic focus areas include Acute Myeloid Leukemia, Sarcoma,Soft Tissue, Leukemia, Myeloid, Acute, Psoriasis, Acute Myeloid Leukaemia (AML). NovaPharmaNews

• Is Moleculin Biotech publicly traded?

  Yes. Moleculin Biotech is listed with ticker MBRX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Moleculin Biotech develop or market?

  We link 10 drug profile(s) where Moleculin Biotech is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/moleculin-biotech#company-drugs.

• What are the latest developments for Moleculin Biotech?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Moleculin Biotech focus on?

  Moleculin Biotech focuses on Acute Myeloid Leukemia, Sarcoma,Soft Tissue, Leukemia, Myeloid, Acute based on our analysis of their pipeline programs and drug development activities.